MIRACLE Medical Technology Act of 2025
HB661, titled the Maximizing Israel-U.S. Research Advancement and Collaborative Leadership in Emerging Medical Technology Act of 2025, would direct the Secretary of Health and Human Services to create and run a federal program to coordinate U.S.-Israel cooperation on health care products and services. The bill is focused on expanding collaboration in research and development, commercialization, regulatory alignment, digital health, disease prevention, and biological product manufacturing. It also contemplates a possible joint U.S.-Israel Health Care Collaboration Center and requires the program to begin within six months of enactment.
The program would cover a broad range of activities, including joint research projects, early-stage clinical trials, health data sharing for research, startup and technology transfer support, telemedicine and interoperability initiatives, cybersecurity and privacy standards, vaccine and infectious disease collaboration, and supply chain resilience for biologics. The bill authorizes $8 million annually for fiscal years 2026 through 2030 to carry out these activities, subject to appropriations.
If enacted, the bill would create a new federal health innovation and international collaboration program within HHS, with consultation from Commerce, CMS’s Council for Technology and Innovation, and FDA. It would not directly amend existing health statutes in the text provided, but it would establish new federal responsibilities and funding for U.S.-Israel cooperation on medical technology, biologics, digital health, regulatory harmonization, and related commercialization efforts. The measure could affect federal agencies, research institutions, manufacturers, startups, and health systems engaged in cross-border health innovation.
The available context suggests a generally favorable or bipartisan posture toward the bill, as it was introduced by members from different parties and referred to committee without recorded opposition or votes in the provided materials. The bill’s framing emphasizes innovation, patient access, and strategic cooperation, which typically draws support from health technology, research, and trade-oriented stakeholders. No committee transcript or vote history is available here to indicate formal debate or resistance.
No specific points of contention are documented in the provided materials, but the bill’s broad scope could raise questions about federal spending, the role of government in international technology coordination, data-sharing and privacy safeguards, intellectual property protection, and regulatory harmonization with a foreign regulator. Potential concerns may also involve whether the proposed collaboration center or joint initiatives duplicate existing public-private or bilateral programs, and how the appropriated funds would be prioritized across research, manufacturing, telemedicine, and regulatory activities.